Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Conditions:   Esophageal Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma
Interventions:   Biological: durvalumab;   Drug: carboplatin AUC 2/paclitaxel;   Radiation: External beam radiation;   Procedure: esophagogastrectomy
Sponsors:   Memorial Sloan Kettering Cancer Center;   AstraZeneca
Recruiting - verified November 2016

http://ift.tt/2extqWn